Clinical trial NCT05907447: A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Official title: A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lymphoma
Extranodal Lymphoma
Diffuse Large B Cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Marginal Zone Lymphoma
Mucosa-Associated Lymphoid Tissue Lymphoma
NK/T-Cell Lymphoma, Nasal and Nasal-Type
Intravascular Large B-Cell Lymphoma
Keywords: LYMPHOMA
EXTRANODAL
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
Collaborators: name: Nanfang Hospital, Southern Medical University
name: Fujian Medical University Union Hospital
name: Peking University Third Hospital
name: Peking University People's Hospital
name: Peking Union Medical College Hospital
name: Beijing Hospital
name: The Second Affiliated Hospital of Dalian Medical University
name: The First Affiliated Hospital of Guangzhou Medical University
name: Henan Provincial People's Hospital
name: Hunan Cancer Hospital
name: Henan Cancer Hospital
name: The First Hospital of Jilin University
name: Wuhan Union Hospital, China
name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
name: Affiliated Hospital of Nantong University
name: The First Affiliated Hospital of Xiamen University
name: Shandong Provincial Hospital
name: Shanxi Province Cancer Hospital
name: RenJi Hospital
name: Beijing Friendship Hospital
name: West China Hospital
name: The First Affiliated Hospital of Soochow University
name: Tongji Hospital
name: Second Affiliated Hospital, School of Medicine, Zhejiang University
name: Sun Yat-sen University
name: Chongqing University Cancer Hospital
name: Anhui Provincial Cancer Hospital
name: The General Hospital of Northern Theater Command
name: Qilu Hospital of Shandong University
name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
name: The Affiliated Hospital Of Guizhou Medical University
name: Wuhan TongJi Hospital
name: General Hospital of Ningxia Medical University
name: The First Affiliated Hospital of Nanchang University
name: The First Affiliated Hospital with Nanjing Medical University
name: Anshan Central Hospital
name: Hainan Cancer Hospital
name: Fifth Affiliated Hospital of Guangzhou Medical University
name: The First Affiliated Hospital of Anhui Medical University
name: The Affiliated Hospital of Xuzhou Medical University
name: First Affiliated Hospital of Harbin Medical University
name: Zhujiang Hospital
First posted: 2023-06-18
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with histologically confirmed diagnosis of non-Hodgkin lymphoma with extranodal involvement or non-Hodgkin lymphoma of rare pathological types attending participating centres.

Brief summary: The aim of this study is to retrospectively collect clinical information on patients with extranodal or rare lymphomas, and to explore the best treatment strategy for these lymphomas in the real-world population.

Detailed description: Lymphoma is a highly common malignant tumor in Asia. For specific extra-abdominal sites or rare pathological subtypes of lymphoma, traditional chemotherapy protocols often cannot provide satisfactory results for patients. This study aims to retrospectively collect clinical information on patients with extranodal lymphoma or rare pathological subtype lymphoma, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the best treatment strategy for these lymphomas in the real-world population.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years (including 18 years old).
2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined; Or patients newly diagnosed with non-Hodgkin lymphoma of rare pathological types, including IVLBCL, SMZL, ALCL, AITL, MALTL.
3. Patients who have received systematic clinical treatment.
4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.

Exclusion Criteria:

1. Patients who only receive supportive treatment.
2. Patients who cannot obtain effective evaluation data of efficacy.

Primary outcomes:
measure: Overall Survival (OS)
timeFrame: Baseline up to data cut-off (up to approximately 1 year)
measure: Progression Free Survival (PFS)
timeFrame: Baseline up to data cut-off (up to approximately 1 year)
Secondary outcomes:
measure: Clinical characteristics form
timeFrame: Baseline up to data cut-off (up to approximately 1 year)
measure: Biological characteristics form
timeFrame: Baseline up to data cut-off (up to approximately 1 year)
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Study officials:
References: